The U.S. General Services Administration has recommended DermTech‘s foundational assay included in the DermTech Melanoma Test (DMT) for coverage by the Veterans Health Administration (VHA), according to a company news release.

This coverage recommendation makes the foundational assay of the DMT available to the VHA’s over 9 million enrolled veterans.

The DermTech Melanoma Test is a noninvasive way to detect melanoma with a greater than 99 percent negative predictive value, according to DermTech.

“We’re honored to join the VHA in bringing our noninvasive melanoma test to America’s Veterans,” Dan Visage, senior vice president of payor access, DermTech,, said in a company news release. “The DMT test results are clinically meaningful and actionable, improve patient care and reduce healthcare costs. We look forward to teaming up with the VHA to make our test widely available to its beneficiaries in the coming months.”